Los Angeles Capital Management LLC Invests $4.19 Million in Catalent, Inc. (NYSE:CTLT)

Los Angeles Capital Management LLC acquired a new stake in Catalent, Inc. (NYSE:CTLT - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 93,199 shares of the company's stock, valued at approximately $4,187,000. Los Angeles Capital Management LLC owned about 0.05% of Catalent at the end of the most recent quarter.

Several other large investors have also modified their holdings of the company. Gladius Capital Management LP purchased a new position in shares of Catalent in the 3rd quarter valued at about $28,000. Exchange Traded Concepts LLC purchased a new position in Catalent during the 3rd quarter valued at about $31,000. GAMMA Investing LLC purchased a new position in Catalent during the 4th quarter valued at about $33,000. Cary Street Partners Investment Advisory LLC increased its holdings in Catalent by 1,162.3% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company's stock valued at $35,000 after acquiring an additional 709 shares in the last quarter. Finally, Rakuten Securities Inc. purchased a new stake in shares of Catalent during the fourth quarter worth about $46,000.

Catalent Price Performance

CTLT stock traded down $0.13 during midday trading on Monday, reaching $56.37. The company had a trading volume of 1,187,678 shares, compared to its average volume of 2,479,066. The stock has a 50 day moving average price of $56.47 and a 200-day moving average price of $49.07. Catalent, Inc. has a 1-year low of $31.45 and a 1-year high of $60.20. The company has a quick ratio of 1.73, a current ratio of 2.48 and a debt-to-equity ratio of 1.34.

Catalent (NYSE:CTLT - Get Free Report) last issued its earnings results on Friday, February 9th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.22). The business had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.01 billion. Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The firm's revenue was down 10.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.62 EPS. Equities research analysts anticipate that Catalent, Inc. will post 0.28 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on CTLT. Stephens reaffirmed an "equal weight" rating and set a $63.50 price target on shares of Catalent in a research report on Thursday, April 4th. UBS Group reiterated a "neutral" rating and set a $63.50 target price (up previously from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. StockNews.com initiated coverage on shares of Catalent in a report on Sunday. They set a "sell" rating for the company. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $63.50 price objective on shares of Catalent in a report on Tuesday, February 20th. Finally, Barclays upped their price target on shares of Catalent from $45.00 to $47.00 and gave the company an "equal weight" rating in a report on Thursday, January 25th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $52.46.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.